echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The head of Novartis Innovative Drugs China confirmed!

    The head of Novartis Innovative Drugs China confirmed!

    • Last Update: 2022-05-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    hot topic

    In recent days, two more multinational pharmaceutical companies have announced major personnel changes



    Novartis business "two-in-one" innovative drug China head confirmed



    On April 22, it was reported that Novartis has identified the regional heads of innovative drugs international, and Zhang Ying, president of Novartis Pharmaceuticals (China), has been appointed as the president and managing director of innovative drugs China



    In recent years, Novartis has achieved steady growth in performance



    Novartis said the streamlined organizational structure and operational setup supports Novartis' focus on pharmaceuticals to power the next phase of innovation, growth and productivity




    Bayer even taps two GSK executives to develop prostate cancer track


    Bayer is also accelerating the adjustment of product pipelines and staffing, especially strengthening its foothold in the field of oncology, investing heavily in expanding research and development pipelines, and collaborating with a number of gene therapy companies



    At present, Bayer has launched 6 products and 10 indications in the global oncology market, with an important focus coming from the new drug Nubeqa for the treatment of prostate cancer



    Notably, Bayer's prostate cancer product matrix is ​​growing, and in addition to Nubeqa, the prostate cancer radiotherapy drug Xofigo has been approved for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases patients with sexually transmitted diseases
    .
    Previously, Bayer also acquired exclusive rights to a differential alpha radionuclide therapy based on actinium-225 and a prostate-specific small molecule antigen (PSMA) targeting through the acquisition of Noria and subsidiary PSMA Therapeutics
    .


    How to maintain high growth in the Chinese market under the tide of global resource integration


    Under the tide of global resource integration of multinational pharmaceutical giants, last year, Pfizer officially replaced the background LOGO of "Blue Pill", which has been used for more than 70 years, with two blue spirals in the shape of a circle.
    The new LOGO marks Pfizer from diversification to focusing on R&D.
    Shifts in prescription drugs and vaccines to prevent and treat disease
    .
    In March of this year, Johnson & Johnson announced that its medical device business was officially renamed "Johnson & Johnson Medical Technology" globally, marking the transformation of Johnson & Johnson Medical into an innovative enterprise centered on patients and driven by business growth
    .


    As an important driving force for the growth of global performance of multinational pharmaceutical companies, the potential of the Chinese market is self-evident, and China is accelerating its integration with the international market
    .
    In the financial reports released by multinational pharmaceutical companies in 2021, the revenue growth rates of Merck and Eli Lilly in China are as high as 60% and 41% respectively
    .
    In recent years, under the influence of multiple factors such as drug review reform, centralized procurement, and medical insurance negotiation, multinational pharmaceutical giants have also initiated a new round of structural adjustment, increased investment in China, focused on core therapeutic areas, and accelerated relying on innovative products.

    .


    Roche China has made adjustments one after another, upgraded and created a customer interaction business model "centered on the field of disease treatment"
    .
    In June last year, under the patient and disease-oriented trend, Roche started the road of "agile transformation" and established a "lymphoma sub-specialty innovation team", focusing on the standardization of lymphoma diagnosis and treatment in China and the survival benefits of lymphoma patients.
    increase, and turn on the "ecosphere mode"
    .
    In December of the same year, Roche announced that it would set up two special areas in Guangdong Province and the Sichuan-Chongqing region to explore the "regional model"
    .


    Merck China merged the digital interaction and transformation and commercial operations divisions to form a new division of business excellence
    .
    MSD China also merged business operations and key account management to create a new business excellence department to accelerate the entry and listing of MSD China
    .
    In addition, a new data protection officer and chief transformation officer have been created
    .


    For multinational companies, a series of measures such as organizational structure adjustment, business line divestiture and merger, and replacement of executives have become the norm.
    "Medicine Economic News" will continue to pay attention to how the Chinese market continues to adjust
    .


    Text editor: Chen Shuwen

    Format editor: Chen Shuwen

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.